Back to today’s briefing

Story perspectives

New Study Enhances Checkpoint Inhibitors for Prostate Cancer

10/25/2025

49 12

Summary

Story summary

Researchers at Memorial Sloan Kettering Cancer Center (MSK) study how to enhance checkpoint inhibitors for prostate cancer.
Checkpoint inhibitors are most effective for MSI-H and MMRd tumors, with about half of MSI-H patients responding.
MSK uses genetic testing to identify patients likely to benefit and to study nonresponse to these treatments.
About 20% of MSI-H prostate cancer patients may have Lynch syndrome, which prompts family testing.

1 of 1

Story summary

Researchers at Memorial Sloan Kettering Cancer Center (MSK) study how to enhance checkpoint inhibitors for prostate cancer.
Checkpoint inhibitors are most effective for MSI-H and MMRd tumors, with about half of MSI-H patients responding.
MSK uses genetic testing to identify patients likely to benefit and to study nonresponse to these treatments.
About 20% of MSI-H prostate cancer patients may have Lynch syndrome, which prompts family testing.